Walter Lauren A, Li Li, Rodgers Joel B, Hess Jennifer J, Skains Rachel M, Delaney Matthew C, Booth James, Hess Erik P
Department of Emergency Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.
Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, AL, United States.
JMIR Res Protoc. 2021 Apr 29;10(4):e18734. doi: 10.2196/18734.
The opioid epidemic has disproportionately impacted areas in the Appalachian region of the United States. Characterized by persistent Medicaid nonexpansion, higher poverty rates, and health care access challenges, populations residing in these areas of the United States have experienced higher opioid overdose death rates than those in other parts of the country. Jefferson County, Alabama, located in Southern Appalachia, has been especially affected, with overdose rates over 2 times greater than the statewide average (48.8 vs 19.9 overdoses per 10,000 persons). Emergency departments (EDs) have been recognized as a major health care source for persons with opioid use disorder (OUD). A program to initiate medications for OUD in the ED has been shown to be effective in treatment retention. Likewise, continued patient engagement in a recovery or treatment program after ED discharge has been shown to be efficient for long-term treatment success.
This protocol outlines a framework for ED-initiated medications for OUD in a resource-limited region of the United States; the study will be made possible through community partnerships with referral resources for definitive OUD care.
When a patient presents to the ED with symptoms of opioid withdrawal, nonfatal opioid overdose, or requesting opioid detoxification, clinicians will consider the diagnosis of OUD using the Diagnostic and Statistical Manual of Mental Disorders (fifth edition) criteria. All patients meeting the diagnostic criteria for moderate to severe OUD will be further engaged and assessed for study eligibility. Recruited subjects will be evaluated for signs and symptoms of withdrawal, treated with buprenorphine-naloxone as appropriate, and given a prescription for take-home induction along with an intranasal naloxone kit. At the time of ED discharge, a peer navigator from a local substance use coordinating center will be engaged to facilitate patient referral to a regional substance abuse coordinating center for longitudinal addiction treatment.
This project is currently ongoing; it received funding in February 2019 and was approved by the institutional review board of the University of Alabama at Birmingham in June 2019. Data collection began on July 7, 2019, with a projected end date in February 2022. In total, 79 subjects have been enrolled to date. Results will be published in the summer of 2022.
ED recognition of OUD accompanied by buprenorphine-naloxone induction and referral for subsequent long-term treatment engagement have been shown to be components of an effective strategy for addressing the ongoing opioid crisis. Establishing community and local partnerships, particularly in resource-limited areas, is crucial for the continuity of addiction care and rehabilitation outcomes.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/18734.
阿片类药物流行对美国阿巴拉契亚地区造成了尤为严重的影响。这些地区长期存在医疗补助计划未扩大、贫困率较高以及医疗服务获取困难等问题,当地居民的阿片类药物过量致死率高于美国其他地区。位于阿巴拉契亚南部的阿拉巴马州杰斐逊县受到的影响尤为严重,其过量用药率比全州平均水平高出两倍多(每万人中有48.8例过量用药,而全州平均为19.9例)。急诊科已被公认为是阿片类药物使用障碍(OUD)患者的主要医疗服务来源。在急诊科启动针对OUD的药物治疗方案已被证明在治疗维持方面是有效的。同样,患者在急诊科出院后持续参与康复或治疗项目已被证明对长期治疗成功是有效的。
本方案概述了在美国资源有限地区由急诊科启动的针对OUD的药物治疗框架;该研究将通过与提供确定性OUD护理的转诊资源建立社区伙伴关系来实现。
当患者因阿片类药物戒断症状、非致命性阿片类药物过量或请求阿片类药物脱毒而前往急诊科时,临床医生将使用《精神疾病诊断与统计手册》(第五版)标准来考虑OUD的诊断。所有符合中度至重度OUD诊断标准的患者将被进一步纳入并评估是否符合研究条件。招募的受试者将接受戒断症状和体征评估,酌情使用丁丙诺啡 - 纳洛酮进行治疗,并开具带回家诱导治疗的处方以及鼻内纳洛酮试剂盒。在急诊科出院时,将安排当地物质使用协调中心的同伴导航员,以促进患者转诊至区域药物滥用协调中心进行长期成瘾治疗。
该项目目前正在进行中;于2019年2月获得资金,并于20年9月获得阿拉巴马大学伯明翰分校机构审查委员会的批准。数据收集于2019年7月7日开始,预计结束日期为2022年2月。截至目前,共招募了79名受试者。结果将于2022年夏季公布。
急诊科对OUD的识别,同时进行丁丙诺啡 - 纳洛酮诱导治疗并转诊至后续长期治疗,已被证明是应对持续的阿片类药物危机的有效策略的组成部分。建立社区和地方伙伴关系,特别是在资源有限的地区,对于成瘾护理和康复结果的连续性至关重要。
国际注册报告识别码(IRRID):DERR1 - 10.2196/18734